APREPITANT in Slovenian translation

• aprepitant
• aprepritant

Examples of using Aprepitant in English and their translations into Slovenian

Aprepitant is used with other medications in adults
Aprepitant v prahu se uporablja skupaj z drugimi zdravili pri odraslih

The potential for effects of fosaprepitant and aprepitant on fertility has not been fully characterised because exposure levels above the therapeutic exposure in humans could not be attained in animal studies.
Možnost vpliva fosaprepitanta in aprepitanta na plodnost ni v celoti raziskana, saj med študijami na živalih niso mogli doseči stopenj izpostavljenosti, ki bi bile višje od stopenj terapevtske izpostavljenosti pri človeku.

The potential for reproductive toxicities of fosaprepitant and aprepitant have not been fully characterised,
Možnost vpliva fosaprepitanta in aprepitanta na sposobnost razmnoževanja ni v celoti raziskana,

The reduction in risk for a vomiting episode over the 0 to 24 hour period with aprepitant 40 mg relative to ondansetron 4 mg was 53.3%(95% C.I.: 35.3 to 66.3) in an analysis that censors patients at the time of rescue use.
Znižanje tveganja za epizodo bruhanja v času 0-24 ur z aprepitantom 40 mg glede na ondansetron 4 mg je bilo 53,3%(95-odstotni IZ: 35,3 do 66,3) v analizi, ki nadzoruje bolnike v času rešilnega zdravljenja.

Alternative or back-up methods of contraception should be used during treatment with fosaprepitant or aprepitant and for 2 months following the last dose of aprepitant(see section 4.5).
Med zdravljenjem s fosaprepitantom ali aprepitantom in še 2 meseca po zadnjem odmerku aprepitanta mora bolnica uporabljati drugo ali dodatno kontracepcijsko metodo(glejte poglavje 4. 5).

The potential for reproductive toxicities of fosaprepitant and aprepitant have not been fully characterized,
Možnost škodljivega vpliva fosaprepitanta in aprepitanta na sposobnost razmnoževanja ni v celoti raziskana,

One case of angioedema and urticaria was reported as a serious adverse event in a patient receiving aprepitant in a non-CINV/ non-PONV study.
Poročali so o enem primeru angioedema in urtikarije kot o resnem neželenem dogodku, vendar pa ne v študiji preprečevanja s kemoterapijo povzročene navzee in bruhanja ali preprečevanja pooperacijske navzee in bruhanja(CINV/ PONV).

A single dose of aprepitant 200 mg on Day 1 co-administered with midazolam,
Uporaba enkratnega odmerka aprepitanta 200 mg 1. dan skupaj z midazolamom, občutljivim substratom CYP3A4,

Interaction studies with aprepitant 165 mg and midazolam have not been conducted; however, the following study with 200 mg of aprepitant should be considered when using EMEND 165 mg with medicinal products metabolised via CYP3A4.
Študije medsebojnega delovanja aprepitanta 165 mg in midazolama niso bile izvedene, vendar pa je pri uporabi zdravila EMEND 165 mg in zdravil, ki se presnavljajo preko CYP3A4, treba upoštevati sledečo študijo z 200 mg aprepitanta.

amprenavir, aprepitant, atazanavir, ciprofloxacin,
amprenavirju, aprepitantu, atazanavirju, ciprofloksacinu,

safety was evaluated for 1,143 patients receiving the 1-day regimen of IVEMEND 150 mg compared to 1,169 patients receiving the 3-day regimen of aprepitant.
so varnost ovrednotili pri 1.143 bolnikih, ki so prejeli 1-dnevni režim zdravljenja z zdravilom IVEMEND 150 mg, in pri 1.169 bolnikih, ki so prejeli 3-dnevni režim zdravljenja z aprepitantom.

the adverse reactions profile was generally similar to that seen in the other HEC studies with aprepitant.
je bil profil neželenih učinkov na splošno podoben tistemu v drugih HEC študijah z aprepitantom.

receiving fosaprepitant in clinical studies or postmarketing that have not been reported with aprepitant as described above.
v obdobju trženja zdravila prejeli fosaprepitant, in o katerih niso poročali pri aprepitantu.

The most common adverse reaction reported at a greater incidence in adults treated with 40 mg aprepitant(1.1%) than with ondansetron(1.0%)
Povečanje vrednosti ALT je bila najpogostejša neželena reakcija, katere pogostnost je bila pri odraslih, ki so prejemali 40 mg aprepitanta večja(1,1%) od pogostnosti pri odraslih,

This benefit shown by EMEND 125 mg capsules given on the first day of chemotherapy can be applied to IVEMEND as the two medicines were shown to produce equivalent levels of aprepitant in the body.
Koristi, ki so jih pokazale 125 mg kapsule zdravila EMEND, zaužite na prvi dan kemoterapije, se lahko pričakujejo tudi pri zdravilu IVEMEND, saj je bilo dokazano, da obe zdravili tvorita enako količino aprepitanta v telesu.

Following a single intravenous dose of fosaprepitant administered as a 15-minute infusion to healthy volunteers the mean AUC0-24hr of aprepitant was 19.8 μ g• hr/ ml and the mean maximal aprepitant concentration was 3.26 μ g/ ml.
Po enkratnem intravenskem odmerku fosaprepitanta v obliki 15- minutne intravenske infuzije je bila pri zdravih prostovoljcih srednja vrednost AUC0- 24ur aprepitanta 19, 8 μg• h/ ml, srednja največja koncentracija aprepitanta pa 3, 26 μg/ ml.

the AUC of pharmacologically active unbound aprepitant was not significantly affected in patients with renal insufficiency compared with healthy subjects.
bolnikih z insuficienco ledvic, se AUC farmakološko aktivnega nevezanega zdravila v primerjavi z zdravimi preiskovanci ni bistveno spremenil.

fosaprepitant Cmax and aprepitant AUC values were up to 3 times and 40 times, respectively, higher than clinical values.
vrednost AUC aprepitanta pa do 40-krat večja od klinične vrednosti.

Methylprednisolone: Interaction studies with aprepitant 165 mg and methylprednisolone have not been conducted; however, the following study with the aprepitant 125 mg/80 mg regimen should be considered when using EMEND 165 mg with methylprednisolone.
Metilprednizolon: Študije medsebojnega delovanja aprepitanta 165 mg in metilprednizolona niso bile izvedene, vendar pa je pri uporabi zdravila EMEND 165 mg in metilprednizolona treba upoštevati sledečo študijo z uporabo aprepitanta po shemi 125 mg/80 mg.

The aprepitant regimen consisted of aprepitant 125 mg on Day 1
Režim zdravljenja z aprepitantom je vključeval aprepitant 125 mg 1. dan,